ES2972205T3 - Pridopidina para el tratamiento del síndrome x frágil - Google Patents

Pridopidina para el tratamiento del síndrome x frágil Download PDF

Info

Publication number
ES2972205T3
ES2972205T3 ES18741607T ES18741607T ES2972205T3 ES 2972205 T3 ES2972205 T3 ES 2972205T3 ES 18741607 T ES18741607 T ES 18741607T ES 18741607 T ES18741607 T ES 18741607T ES 2972205 T3 ES2972205 T3 ES 2972205T3
Authority
ES
Spain
Prior art keywords
pharmaceutical composition
pridopidine
use according
subject
fxs
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES18741607T
Other languages
English (en)
Spanish (es)
Inventor
Michael Hayden
Mahmoud Pouladi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prilenia Neurotherapeutics Ltd
Agency for Science Technology and Research Singapore
National University of Singapore
Original Assignee
Prilenia Neurotherapeutics Ltd
Agency for Science Technology and Research Singapore
National University of Singapore
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd, Agency for Science Technology and Research Singapore, National University of Singapore filed Critical Prilenia Neurotherapeutics Ltd
Application granted granted Critical
Publication of ES2972205T3 publication Critical patent/ES2972205T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
ES18741607T 2017-01-20 2018-01-18 Pridopidina para el tratamiento del síndrome x frágil Active ES2972205T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762448595P 2017-01-20 2017-01-20
PCT/US2018/014169 WO2018136600A1 (en) 2017-01-20 2018-01-18 Use of pridopidine for the treatment of fragile x syndrome

Publications (1)

Publication Number Publication Date
ES2972205T3 true ES2972205T3 (es) 2024-06-11

Family

ID=62908348

Family Applications (1)

Application Number Title Priority Date Filing Date
ES18741607T Active ES2972205T3 (es) 2017-01-20 2018-01-18 Pridopidina para el tratamiento del síndrome x frágil

Country Status (13)

Country Link
US (2) US11234973B2 (cg-RX-API-DMAC7.html)
EP (1) EP3570940B1 (cg-RX-API-DMAC7.html)
JP (1) JP7114604B2 (cg-RX-API-DMAC7.html)
CN (1) CN110505902B (cg-RX-API-DMAC7.html)
AU (1) AU2018210145B2 (cg-RX-API-DMAC7.html)
BR (1) BR112019015000A2 (cg-RX-API-DMAC7.html)
CA (1) CA3050700C (cg-RX-API-DMAC7.html)
DK (1) DK3570940T3 (cg-RX-API-DMAC7.html)
ES (1) ES2972205T3 (cg-RX-API-DMAC7.html)
HU (1) HUE068300T2 (cg-RX-API-DMAC7.html)
IL (1) IL268125B2 (cg-RX-API-DMAC7.html)
PL (1) PL3570940T3 (cg-RX-API-DMAC7.html)
WO (1) WO2018136600A1 (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013536825A (ja) 2010-09-03 2013-09-26 イバックス・インターナショナル・ゲーエムベーハー ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
EP3503890B1 (en) 2016-08-24 2024-12-18 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating dystonias
MX390627B (es) 2016-08-24 2025-03-21 Prilenia Neurotherapeutics Ltd Uso de pridopidina para el tratamiento de la disminucion funcional.
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
CN111343982A (zh) 2017-09-08 2020-06-26 普瑞尼亚神经治疗有限公司 用于治疗药物诱发的异动症的普利多匹定
BR112021015346A2 (pt) 2019-02-04 2021-10-05 Prilenia Neurotherapeutics Ltd. Uso de pridopidina de baixa dose para a doença de parkinson e outras doenças associadas ao parkinsonismo
JP7490064B2 (ja) * 2020-01-08 2024-05-24 ニューロヴェンティ カンパニー リミテッド リスリード化合物を有効成分として含む脆弱ｘ症候群または関連発達障害治療用組成物
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
USRE46117E1 (en) 1999-12-22 2016-08-23 Teva Pharmaceuticals International Gmbh Modulators of dopamine neurotransmission
CA2584831C (en) 2004-10-13 2013-09-17 Neurosearch Sweden Ab Process for the synthesis of 4-(3-methanesulfonylphenyl)-1-n-propyl-piperidine
WO2008127188A1 (en) 2007-04-12 2008-10-23 Allbay Ab N-oxide and/or di-n-oxide derivatives of dopamine receptor stabilizers/modulators displaying improved cardiovascular side-effects profiles
TW200848063A (en) * 2007-04-23 2008-12-16 Combinatorx Inc Methods and compositions for the treatment of neurodegenerative disorders
JP2013532233A (ja) 2010-07-02 2013-08-15 アクティエボラゲット・エスコーエッフ 機械構成要素、および表面硬化方法
JP2013536825A (ja) 2010-09-03 2013-09-26 イバックス・インターナショナル・ゲーエムベーハー ドパミン作動性安定化剤として有用なプリドピジンの重水素化類似体
PL2667715T3 (pl) * 2011-01-27 2018-02-28 Neuren Pharmaceuticals Limited Leczenie zaburzeń spektrum autystycznego z wykorzystaniem kwasu glicylo-l- 2-metyloprolilo-l-glutaminowego
EP2753603B1 (en) 2011-09-07 2017-06-21 Teva Pharmaceuticals International GmbH Polymorphic form of pridopidine hydrochloride
WO2013086425A1 (en) 2011-12-08 2013-06-13 IVAX International GmbH The hydrobromide salt of pridopidine
US20130267552A1 (en) 2012-04-04 2013-10-10 IVAX International GmbH Pharmaceutical compositions for combination therapy
CN104768545A (zh) * 2012-09-27 2015-07-08 泰华制药工业有限公司 雷沙吉兰和普多比啶组合以治疗神经退化性病症,尤其亨廷顿氏病
UA122999C2 (uk) 2013-06-21 2021-02-03 Прайлінія Н'Юротерапьютікс Лтд. Застосування придопідину для лікування хвороби гантінгтона
JP6949487B2 (ja) 2014-01-22 2021-10-13 プリレニア・ニューロセラピューティクス・エルティーディーＰｒｉｌｅｎｉａ Ｎｅｕｒｏｔｈｅｒａｐｅｕｔｉｃｓ Ｌｔｄ プリドピジンの調節放出製剤
TW201613859A (en) 2014-06-30 2016-04-16 Teva Pharma Analogs of PRIDOPIDINE, their preparation and use
CA2970799A1 (en) 2014-12-22 2016-06-30 Teva Pharmaceuticals International Gmbh L-tartrate salt of pridopidine
EP4282479A3 (en) 2015-02-25 2024-02-21 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
WO2016138135A1 (en) 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease

Also Published As

Publication number Publication date
JP7114604B2 (ja) 2022-08-08
CN110505902B (zh) 2022-11-11
IL268125B2 (en) 2023-04-01
EP3570940A4 (en) 2020-10-28
PL3570940T3 (pl) 2024-06-17
EP3570940B1 (en) 2023-12-13
IL268125B (en) 2022-12-01
HUE068300T2 (hu) 2024-12-28
DK3570940T3 (da) 2024-02-19
US20220202798A1 (en) 2022-06-30
WO2018136600A1 (en) 2018-07-26
US20190336488A1 (en) 2019-11-07
BR112019015000A2 (pt) 2020-04-07
CA3050700A1 (en) 2018-07-26
EP3570940A1 (en) 2019-11-27
AU2018210145B2 (en) 2023-06-29
AU2018210145A1 (en) 2019-08-29
JP2020514313A (ja) 2020-05-21
IL268125A (en) 2019-09-26
CN110505902A (zh) 2019-11-26
CA3050700C (en) 2023-10-03
US11234973B2 (en) 2022-02-01

Similar Documents

Publication Publication Date Title
ES2972205T3 (es) Pridopidina para el tratamiento del síndrome x frágil
ES2938546T3 (es) Método de tratamiento de la esclerosis lateral amiotrófica con pridopidina
ES2586843T3 (es) Tratamiento de trastornos relacionados con BDNF usando laquinimod
ES2678794T3 (es) Terapia para trastornos neurológicos basada en baclofeno y acamprosato
ES2733954T3 (es) Composición que comprende torasemida y baclofeno para tratar trastornos neurológicos
ES2897453T3 (es) Aplicación de R-ketamina y sal de la misma como productos farmacéuticos
ES2930628T3 (es) Uso de pridopidina para mejorar la memoria
ES2690490T3 (es) Nuevas composiciones para tratar trastornos neurológicos
ES3031271T3 (en) Use of pridopidine for the treatment of anxiety and depression
ES2344313T3 (es) Composiciones farmaceuticas de un esteroide neuroactivo y usos de las mismas.
ES2690061T3 (es) Composiciones para tratar la enfermedad de Parkinson
KR20100024951A (ko) 세포를 자극하기 위한 방법 및 조성물
CN116267014A (zh) 环状氘化加波沙朵及其用于治疗精神障碍的用途
Yang et al. Human basic fibroblast growth factor inhibits tau phosphorylation via the PI3K/Akt-GSK3β signaling pathway in a 6-Hydroxydopamine-Induced model of Parkinson's Disease
RS57763B1 (sr) Tauroursodezoksiholinska kiselina (tudca) za upotrebu u lečenju neurodegenerativnih poremećaja
ES2931104T3 (es) Uso de 2-fenil-6-(1H-imidazol-1-il)quinazolina para el tratamiento de enfermedades neurodegenerativas, preferentemente la enfermedad de Alzheimer
ES2987108T3 (es) Nuevos moduladores del receptor de tipo A de ácido gamma aminobutírico para los trastornos del estado de ánimo
Lee et al. The effects of Korean Red Ginseng-derived components on oligodendrocyte lineage cells: Distinct facilitatory roles of the non-saponin and saponin fractions, and Rb1, in proliferation, differentiation and myelination
ES3014042T3 (en) Trans-10-hydroxy-2-decenoic acid for use in the treatment of autism spectrum disorder
ES2729208T3 (es) Terapia basada en baclofeno y acamprosato de trastornos de degeneración macular
Class et al. Patent application title: USE OF PRIDOPIDINE FOR THE TREATMENT OF FRAGILE X SYNDROME Inventors: Michael Hayden (Herzliya, IL) Mahmoud Abdulhossein Pouladi (Singapore, SG) Assignees: PRILENIA NEUROTHERAPEUTICS LTD. NATIONAL UNIVERSITY OF SINGAPORE Agency For Science, Technology and Research
Kokane et al. Impact of early life ketamine exposure on the developing brain and cognitive sequelae: a discussion of apoptotic neurodegeneration mechanisms
HK40016661B (en) Pridopidine for use in the treatment of fragile x syndrome
HK40016661A (en) Pridopidine for use in the treatment of fragile x syndrome
BR112021004938A2 (pt) métodos e composições para tratamento de danos associados com o envelhecimento usando inibidores de ccr3